Obstet Gynecol Sci.  2020 Jul;63(4):407-416. 10.5468/ogs.20020.

Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus

• Amirian A
• Mahani MB
• Abdi F

• KMID: 2505030
• DOI: http://doi.org/10.5468/ogs.20020

Abstract

Gestational diabetes mellitus (GDM) is the most common pregnancy-associated metabolic disorder that is steadily increasing worldwide. Early diagnosis of pregnant women susceptible to GDM is the first step for deploying effective preventive treatment to reduce maternal, fetal, and neonatal complications. The diagnostic process of GDM is still controversial and interleukin-6 (IL-6) is one of the most recent markers used for the diagnosis of GDM. In this study, we aimed to systematically review the role of IL-6 in the diagnosis of GDM. In this systematic review, Google Scholar, Scopus, PubMed, ISI Web of Science, ProQuest, and MEDLINE databases were searched using the following keywords: GDM, screening, and IL-6, with the time interval 2009–2020. The quality of articles was assessed using the Strengthening the Reporting of Observational Studies in Epidemiology checklist. Twenty-four articles with desired quality that met the inclusion criteria were selected and reviewed further. Sixteen studies showed a statistically significant association, while 8 studies did not report any relationship between IL-6 levels and GDM. Based on the results of these studies, assessing the serum IL-6 levels can be investigated a newly established diagnostic biomarker for GDM. Therefore, through early diagnosis of susceptible women, effective measures can be implemented to reduce its complications.

Keyword

Diabetes, gestational; Screening; IL-6

Figure

• 

  Fig. 1. Flow diagram for searching the articles.

• 

  Fig. 2. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) score of different studies.

• 

  Fig. 3. Trimester in which the interleukin-6 test was performed.

• 

  Fig. 4. Assessing the significance level of different studies.

Reference

References

1. World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organization;2019.

2. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019; 42:S13–28.

3. Koivusalo SB, Rönö K, Klemetti MM, Roine RP, Lindström J, Erkkola M, et al. Gestational diabetes mellitus can be prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study (RADIEL): a randomized controlled trial. Diabetes Care. 2016; 39:24–30.

4. Sudharshana Murthy KA, Bhandiwada A, Chandan SL, Gowda SL, Sindhusree G. Evaluation of oxidative stress and proinflammatory cytokines in gestational diabetes mellitus and their correlation with pregnancy outcome. Indian J Endocrinol Metab. 2018; 22:79–84.

5. Durnwald C. Diabetes mellitus in pregnancy: screening and diagnosis [Internet]. Waltham (MA): UpToDate, Inc;c2019 [cited 2019 Nov 25]. Available from: https://www.uptodate.com/contents/diabetes-mellitus-in-pregnancyscreening-and-diagnosis.

6. Caughey AB. Gestational diabetes mellitus: obstetric issues and management [Internet]. Waltham (MA): UpToDate, Inc;c2019 [cited 2019 Nov 30]. Available from: https://www.uptodate.com/contents/gestationaldiabetes-mellitus-obstetric-issues-and-management.

7. Song C, Li J, Leng J, Ma RC, Yang X. Lifestyle intervention can reduce the risk of gestational diabetes: a meta-analysis of randomized controlled trials. Obes Rev. 2016; 17:960–9.

8. Mirghani Dirar A, Doupis J. Gestational diabetes from A to Z. World J Diabetes. 2017; 8:489–511.

9. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams obstetrics. 25th ed. New York (NY): Mcgraw-hill;2018.

10. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization;2013.

11. Amreen S, Suneel A, Shetty A, Vasudeva A, Kumar P. Use of glycosylated HbA1c and random blood sugar as a screening tool for gestational diabetes mellitus in first trimester. Int J Reprod Contracept Obstet Gynecol. 2018; 7:524–8.

12. Huhn EA, Rossi SW, Hoesli I, Göbl CS. Controversies in screening and diagnostic criteria for gestational diabetes in early and late pregnancy. Front Endocrinol (Lausanne). 2018; 9:696.

13. Siddiqui S, Waghdhare S, Goel C, Panda M, Soneja H, Sundar J, et al. Augmentation of IL-6 production contributes to development of gestational diabetes mellitus: an Indian study. Diabetes Metab Syndr. 2019; 13:895–9.

14. Suzuki T, Imai J, Yamada T, Ishigaki Y, Kaneko K, Uno K, et al. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic β-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes. 2011; 60:537–47.

15. Lainampetch J, Panprathip P, Phosat C, Chumpathat N, Prangthip P, Soonthornworasiri N, et al. Association of tumor necrosis factor alpha, interleukin 6, and C-reactive protein with the risk of developing type 2 diabetes: a retrospective cohort study of rural thais. J Diabetes Res. 2019; 2019:9051929.

16. Yang Y, Liu L, Liu B, Li Q, Wang Z, Fan S, et al. Functional defects of regulatory T cell through interleukin 10 mediated mechanism in the induction of gestational diabetes mellitus. DNA Cell Biol. 2018; 37:278–85.

17. Braga FO, Negrato CA, Matta MFBD, Carneiro JR, Gomes MB. Relationship between inflammatory markers, glycated hemoglobin and placental weight on fetal outcomes in women with gestational diabetes. Arch Endocrinol Metab. 2019; 63:22–9.

18. Šimják P, Cinkajzlová A, Anderlová K, Kloučková J, Kratochvílová H, Lacinová Z, et al. Changes in plasma concentrations and mRNA expression of hepatokines fetuin A, fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus. Physiol Res. 2018; 67:S531–42.

19. Abdi F, Ozgoli G, Rahnemaie FS. A systematic review of the role of vitamin D and calcium in premenstrual syndrome. Obstet Gynecol Sci. 2019; 62:73–86.

20. Rahnemaie FS, Zare E, Zaheri F, Abdi F. Effects of complementary medicine on successful breastfeeding and its associated issues in the postpartum period. Iran J Pediatr. 2019; 29:e80180.

21. Wang X, Liu J, Wang D, Zhu H, Kang L, Jiang J. Expression and correlation of Chemerin and FABP4 in peripheral blood of gestational diabetes mellitus patients. Exp Ther Med. 2020; 19:710–6.

22. Yu H, Liu Z, Dong S. Changes in intestinal flora, TNF-α, L-17, and IL-6 levels in patients with gestational diabetes mellitus. Eur J Inflamm;Forthcoming 2018.

23. Zhao X, Liu J, Shen L, Wang A, Wang R. Correlation between inflammatory markers (hs-CRP, TNF-α, IL-1β, IL-6, IL-18), glucose intolerance, and gestational diabetes mellitus in pregnant women. Int J Clin Exp Med. 2018; 11:8310–6.

24. Abell SK, Shorakae S, Harrison CL, Hiam D, MorenoAsso A, Stepto NK, et al. The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes. Diabetes Metab Res Rev. 2017; 33:e2926.

25. Zhang J, Chi H, Xiao H, Tian X, Wang Y, Yun X, et al. Interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) single nucleotide polymorphisms (SNPs), inflammation and metabolism in gestational diabetes mellitus in Inner Mongolia. Med Sci Monit. 2017; 23:4149–57.

26. Bossick AS, Peters RM, Burmeister C, Kakumanu N, Shill JE, Cassidy-Bushrow AE. Antenatal inflammation and gestational diabetes mellitus risk among pregnant African-American women. J Reprod Immunol. 2016; 115:1–5.

27. Oztop N, Kusku-Kiraz Z, Dervisoglu E, Dinccag N, Genc S. The association of glycemic markers with plasma adipocytokine levels in women with gestational diabetes. J Diabetes Metab. 2016; 7:1000699.

28. Qu X, Yu H, Jia B, Yu X, Cui Q, Liu Z, et al. Association of downregulated HDAC 2 with the impaired mitochondrial function and cytokine secretion in the monocytes/macrophages from gestational diabetes mellitus patients. Cell Biol Int. 2016; 40:642–51.

29. Gümüş P, Özçaka Ö, Ceyhan-Öztürk B, Akcali A, Lappin DF, Buduneli N. Evaluation of biochemical parameters and local and systemic levels of osteoactive and B-cell stimulatory factors in gestational diabetes in the presence or absence of gingivitis. J Periodontol. 2015; 86:387–97.

30. Hassiakos D, Eleftheriades M, Papastefanou I, Lambrinoudaki I, Kappou D, Lavranos D, et al. Increased maternal serum interleukin-6 concentrations at 11 to 14 weeks of gestation in low risk pregnancies complicated with gestational diabetes mellitus: development of a prediction model. Horm Metab Res. 2016; 48:35–41.

31. Kim SY, Sy V, Araki T, Babushkin N, Huang D, Tan D, et al. Total adiponectin, but not inflammatory markers Creactive protein, tumor necrosis factor-α, interluekin-6 and monocyte chemoattractant protein-1, correlates with increasing glucose intolerance in pregnant Chinese-Americans. J Diabetes. 2014; 6:360–8.

32. Kuźmicki M, Telejko B, Lipińska D, Pliszka J, Wilk J, Wawrusiewicz-Kurylonek N, et al. The IL-6/IL-6R/sgp130 system and Th17 associated cytokines in patients with gestational diabetes. Endokrynol Pol. 2014; 65:169–75.

33. Nergiz S, Altınkaya ÖS, Küçük M, Yüksel H, Sezer SD, Kurt Ömürlü İ, et al. Circulating galanin and IL-6 concentrations in gestational diabetes mellitus. Gynecol Endocrinol. 2014; 30:236–40.

34. Özyer Ş, Engin-Üstün Y, Uzunlar Ö, Katar C, Danışman N. Inflammation and glycemic tolerance status in pregnancy: the role of maternal adiposity. Gynecol Obstet Invest. 2014; 78:53–8.

35. Mrizak I, Arfa A, Fekih M, Debbabi H, Bouslema A, Boumaiza I, et al. Inflammation and impaired endotheliumdependant vasodilatation in non obese women with gestational diabetes mellitus: preliminary results. Lipids Health Dis. 2013; 12:93.

36. Abdel Gader AG, Khashoggi TY, Habib F, Awadallah SB. Haemostatic and cytokine changes in gestational diabetes mellitus. Gynecol Endocrinol. 2011; 27:356–60.

37. Morisset AS, Dubé MC, Côté JA, Robitaille J, Weisnagel SJ, Tchernof A. Circulating interleukin‐6 concentrations during and after gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2011; 90:524–30.

38. Pöyhönen-Alho M, Ebeling P, Saarinen A, Kaaja R. Decreased variation of inflammatory markers in gestational diabetes. Diabetes Metab Res Rev. 2011; 27:269–76.

39. Kuzmicki M, Telejko B, Szamatowicz J, Zonenberg A, Nikolajuk A, Kretowski A, et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol. 2009; 25:258–63.

40. Harrison CL, Lombard CB, East C, Boyle J, Teede HJ. Risk stratification in early pregnancy for women at increased risk of gestational diabetes. Diabetes Res Clin Pract. 2015; 107:61–8.

41. Farrar D, Duley L, Dowswell T, Lawlor DA. Different strategies for diagnosing gestational diabetes to improve maternal and infant health. Cochrane Database Syst Rev. 2017; 8:CD007122.

42. Weinert LS. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: comment to the International Association of Diabetes and Pregnancy Study Groups consensus panel. Diabetes Care. 2010; 33:e97.

43. Kleiblova P, Dostalova I, Bartlova M, Lacinova Z, Ticha I, Krejci V, et al. Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Mol Cell Endocrinol. 2010; 314:150–6.

44. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, Meshkani R. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl Res. 2016; 167:228–56.

45. Sun D, Li F, Zhang Y, Xu X. Associations of the prepregnancy BMI and gestational BMI gain with pregnancy outcomes in Chinese women with gestational diabetes mellitus. Int J Clin Exp Med. 2014; 7:5784–9.

46. Vejrazkova D, Vcelak J, Vankova M, Lukasova P, Bradnova O, Halkova T, et al. Steroids and insulin resistance in pregnancy. J Steroid Biochem Mol Biol. 2014; 139:122–9.